X4 Pharmaceuticals/XFOR

$1.26

5%
-
1D1W1MYTD1YMAX

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4, that is being developed as an oral, once-daily therapy. It has developed a pipeline of small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.

Ticker

XFOR

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Paula Ragan

Employees

93

Headquarters

Boston, United States

XFOR Metrics

BasicAdvanced
$200.69M
Market cap
-
P/E ratio
-$0.60
EPS
0.49
Beta
-
Dividend rate
$200.69M
0.48984
$2.58
$0.57
2.31M
5.34
106.793
106.793
-66.81%
-161.67%
-78.53%
3.916
5.947
67.73%

What the Analysts think about XFOR

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 7 analysts.
181.75% upside
High $5.00
Low $1.00
$1.26
Current price
$3.55
Average price target

XFOR Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-19.1M
730.43%
Profit margin
0%
-

XFOR Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 34.58%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.16
-$0.33
-$0.01
-$0.10
-
Expected
-$0.22
-$0.16
-$0.15
-$0.15
-$0.16
Surprise
-26.32%
102.04%
-93.28%
-34.58%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for X4 Pharmaceuticals stock?

X4 Pharmaceuticals (XFOR) has a market cap of $200.69M as of April 20, 2024.

What is the P/E ratio for X4 Pharmaceuticals stock?

The price to earnings (P/E) ratio for X4 Pharmaceuticals (XFOR) stock is 0 as of April 20, 2024.

Does X4 Pharmaceuticals stock pay dividends?

No, X4 Pharmaceuticals (XFOR) stock does not pay dividends to its shareholders as of April 20, 2024.

When is the next X4 Pharmaceuticals dividend payment date?

X4 Pharmaceuticals (XFOR) stock does not pay dividends to its shareholders.

What is the beta indicator for X4 Pharmaceuticals?

X4 Pharmaceuticals (XFOR) has a beta rating of 0.49. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the X4 Pharmaceuticals stock price target?

The target price for X4 Pharmaceuticals (XFOR) stock is $3.55, which is 181.75% above the current price of $1.26. This is an average based on projections from 7 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell X4 Pharmaceuticals stock

Buy or sell X4 Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing